SNY vs. BMY, BIIB, JNJ, MRK, ABBV, AZN, NVS, ABT, PFE, and VRTX
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Bristol-Myers Squibb (BMY), Biogen (BIIB), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.
Sanofi (NASDAQ:SNY) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
Bristol-Myers Squibb has lower revenue, but higher earnings than Sanofi. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb received 1046 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 66.89% of users gave Bristol-Myers Squibb an outperform vote while only 53.23% of users gave Sanofi an outperform vote.
Sanofi has a net margin of 10.52% compared to Bristol-Myers Squibb's net margin of -13.50%. Sanofi's return on equity of 26.25% beat Bristol-Myers Squibb's return on equity.
Sanofi presently has a consensus price target of $55.00, suggesting a potential upside of 12.18%. Bristol-Myers Squibb has a consensus price target of $60.00, suggesting a potential upside of 46.02%. Given Bristol-Myers Squibb's higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Sanofi.
Sanofi has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
In the previous week, Bristol-Myers Squibb had 12 more articles in the media than Sanofi. MarketBeat recorded 31 mentions for Bristol-Myers Squibb and 19 mentions for Sanofi. Bristol-Myers Squibb's average media sentiment score of 0.78 beat Sanofi's score of 0.60 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.
10.0% of Sanofi shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Sanofi pays an annual dividend of $1.48 per share and has a dividend yield of 3.0%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.8%. Sanofi pays out 74.4% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Sanofi and Bristol-Myers Squibb tied by winning 10 of the 20 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
